Bioversys N — Investor Presentation 2025

Apr 30, 2025

SAVING LIVES IN RESISTANT TIMES

April 2025

April 2025| BioVersys – Proprietary Material

FORWARD LOOKING STATEMENTS

This presentation (the "Presentation") has been prepared by BioVersys AG ("the Company" and together with its subsidiaries, "we", "us" or the "Group") solely for informational purposes and should be read in conjunction.

Certain statements in this Presentation are forward-looking statements, beliefs or opinions, including statements relating to, among other things, the Company's business, financial condition, future performance, results of operation, potential new market opportunities, growth strategies, and expected growth in the markets in which the Group operates. In some cases, these forward-looking statements may be identified by the use of forward-looking terminology, including the terms "targets", "plans", "believes", "estimates", "anticipates", " expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or similar expressions. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ materially from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which the Group operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting the Group's markets, and other factors beyond the control of the Group). The Company is providing the information in this Presentation as of this date and neither the Company nor any of its respective directors, officers, employees, agents, affiliates, advisors or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this Presentation. Statements contained in this Presentation regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, the Company has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.

2

1 Executive Summary

AMR (Anti-Microbial Resistance): Market Opportunity

3 Pipeline Portfolio

BV100 A

B

C

Alpibectir

Next Generation Candidates & Discovery Platforms

D AMR – Upside Potential

4 Financials

5 Closing Observations

1. EXECUTIVE SUMMARY

TODAY'S PRESENTERS

Marc Gitzinger Chief Executive Officer, Founder

10+ years biotech executive & entrepreneur BEAM Alliance Board President; AMR Industry Alliance Board

Hernan Levett

Chief Financial Officer

30+ yearsfinance and management experience; CFO of Spexis, CFO of Auris Medical; Group Controlling Head at Acino, VP of Europe Finance at InterMune

COMPELLING INVESTMENT OPPORTUNITY

Significantly de-risked lead assets

Clear Phase 3 development path for lead asset Robust preclinical and clinical data package

Strong shareholder base

Cash position CHF 32.6 million as of December 31, 2024

Clear commercial outlook and positioning

Focus on life threatening diseases Upside potential from changing reimbursement environment

2 from leading investors Assets in Clinical Phase 2 (BV100 – phase 3 ready), incl. FDA QIDP designation

• CHF 93m Total Equity money raised
• +CHF 77m IPO SIX February 2025
• 2 Preclinical assets CHF 21m Non-dilutive funding AMR a global health threat

Discovery programs + platforms Equity investment from Large CHF 24m Loan facility from the EIB and Basler Kantonalbank

S C I E N C E F I N A N C E C O R P O R A T E

Credible, founder-led team with vast experience in developing antibacterial drugs

Pharma

Source: Company information.

COMPANY RESEARCH & DEVELOPMENT STRATEGY

BV100 Hospital infections Acinetobacter baumannii (VABP/HABP & BSI) Alpibectir Tuberculosis: • Multi-drug resistant • TB-Meningitis BV500 CF and COPD: Non-tuberculosis mycobacterial infection BV200 Atopic dermatitis Staphylococcus aureus Industry partnerships / collaborations Non-dilutive financing Ansamycin Discovery Platform TRIC Platform Enhance existing drug profile Phase 2 Preclinical Early Stage (BV Discovery) Phase 3 ready

Source: Company information. Note: CF: Cystic Fibrosis; COPD: Chronic Obstructive Pulmonary Disease; VABP: Ventilator Associated Bacterial Pneumonia; HABP: Hospital Acquired Bacterial Pneumonia; BSI: Blood Stream Infections; TRIC: Transcriptional Regulator Inhibitory Compounds.

INNOVATIVE, DIVERSE AND DE-RISKED PIPELINE

Next-Generation Antimicrobial Drugs, Two Proprietary Platforms

Program	Indication	R&D/Preclinical	Phase 1	Phase 2	Phase 3	Expected Key Catalyst	Commercial Rights	Designation
BV100 Novel MoA Rifabutin IV form. Ansamycin platform	Hospital infections Acinetobacterbaumannii (VABP/HABP & BSI)					Phase 3 FPFV: H2 2025		P QIDP
Alpibectir New Antibiotic Class Eto-potentiator TRIC platform	Tuberculosis: • Multi-drug resistant • TB-Meningitis					TBM Phase 2b: H1 2026 Pulmonary TB Phase 2a/b: H1 2025		P QIDP Orphan Drug
BV200 Anti-virulence TRIC platform	Atopic dermatitis Staphylococcus aureus					IND Filing: H1 2027
BV500 Ansamycin platform	CF and COPD: Non-tuberculous mycobacteria infection					IND Filing: H2 2026
BV Discovery	Targets undisclosed

Source: Company information. Note: Data as of September 06, 2024; VABP: Ventilator Associated Bacterial Pneumonia; HABP: Hospital Acquired Bacterial Pneumonia; BSI: Blood Stream Infections; Eto: Ethionamide; FDA QIDP: FDA Qualified Infectious Disease Product Designation: 5 years additional market exclusivity (until 2045 for BV100) and the possibility of fast-track approval; MoA: Mechanism of Action; IND: Investigational New Drug; CF: Cystic Fibrosis; COPD: Chronic Obstructive Pulmonary Disease.

AMR (Anti-MICROBIAL RESISTANCE): MARKET OPPORTUNITY

A MATTER OF TIME

Anti-Microbial Resistance On Track to Kill more People than all Cancers Together¹

1.27M deaths globally attributable to AMR2,5

~5M deaths globally associated with AMR 2,5

surgery can become life-threatening Any 2

leading cause of death globally for the 9.8m patients receiving cancer chemotherapy is infection³

nd ~20%

of hospitalized Covid-19 patients contracted bacterial superinfections⁴

Note: 1. Comparing all cancer-attributable deaths in 2014 vs. 2050 projections for AMR-attributable deaths, The Review on Antimicrobial Resistance, Chaired by Jim O'Neill, 2014; 2. Murray, C.J.L, et al. The Lancet VOLUME 399, February 12, 2022; 3. Elfaituri et.al. Journal of Clinical Oncology, May 26, 2019; 4. Muzuuza et.al. PLoS ONE, May 2021; 5. 2019 figures. 9

SOLVING THE RIDDLE – SUSTAINABLE PROFITABILITY IN TODAY'S REIMBURSEMENT SYSTEM

Source: Company information. Note: SoC: Standard of Care; UTI: Urinary Tract Infection; IAI: Intra-abdominal Infection; SSSI: Skin and Skin-Structure Infection; TB-M: Tuberculosis Meningitis; MDR: Muti-drug Resistant.

BioVersys' products are designed for time sensitive, life-threatening infections with limited available treatment options

SOLVING THE AMR COMMERCIAL UPTAKE

Keys to Commercial Success

BioVersys Approach

Source: Company information. Note: 1. Zyvox and Cubicin; MRSA: Methicillin-resistant Staphylococcus aureus. UTI: Urinary Tract Infection; ABSSI: Acute Bacterial Skin and Skin Structure Infections; API: Active Pharmaceutical Ingredient; IDSA: Infectious Diseases Society of America; DRG: Diagnosis-related Group; NTAP: New Technology Add-on Payment; KOL: Key Opinion Leader.

Combining the right product, right indication, right clinical development strategy and right commercial setup delivers returns in AMR – addressing the unmet medical need that exists today

ANTIBIOTIC DE-RISKING OCCURS EARLIER THAN IN OTHER TAS

Source: 1. Wouters et.al., "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018", JAMA. 2020;323(9):844–853. doi:10.1001/jama.2020.1166. Note: As of September 06, 2024. TA: Therapeutic Area; PK: Pharmacokinetics; PD: Pharmacodynamics.

Greater probability of technical success for anti-infectives

BV100:

Severe hospital infections caused by carbapenem resistant Acinetobacter baumannii

BV100 TARGETING CARBAPENEM-RESISTANT ACINETOBACTER (CRAB) IN PNEUMONIA

WORKHORSE ANTIBIOTIC CLASS IS FAILING

>50% Overall Resistance Against Carbapenems (CRAB)

Source: Management estimate. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis - The Lancet 2022; 399: 629–55 Modeled estimates based on 2019 actuals, by the 'Antimicrobial Resistance Collaborators'. "BV100 Major Markets" include US, France, UK, Italy, Germany, Spain, Austria, Portugal, Switzerland, Sweden, Belgium, Czech Republic, Denmark, Finland, Greece, Netherlands, Norway and Poland. "BV100 China and BV100 Emerging Markets" include Urban China (as defined by the DRG), Brazil, Mexico, South Korea and Turkey.

BV100 addresses an urgent call for action

BV100 – A DIFFERENTIATED DRUG WITH A NEW MOA

Superior Drug Characteristics

Patent Protection / Exclusivity: 2040 (+5 years in the US¹ )

Proprietary formulation and novel mode of action

Increased drug penetration potential

Greater efficacy against MDR A. baumannii vs SoC

Source: Company information. Note: MoA: Mode of Action; FhuE: Membrane protein acting as a receptor; MDR: Multidrug resistant; SoC: Standard of Care. 1. Due to QIDP designation by FDA received in May 2019.

SUMMARY OF PHASE 1 CLINICAL STUDIES

7 Phase 1 Studies Have Been Completed (SAD, MAD, 2xDDI, RI, HI, BAL)

BV100 was considered safe and well tolerated

No dose adjustment of BV100 was necessary for patients with all degrees of impaired renal function

No dose adjustment of BV100 was necessary for patients with mild, moderate or severe hepatic impairment is anticipated

BV100 was a mild inducer of CYP3A4 enzyme. The midazolam (index substrate) AUC decreased by <50%¹ . No dose adjustment is anticipated

The mean Cmax, AUC0-24 and AUC0-inf of rifabutin were 14%, 26% and 69% higher after BV100 was administered with Itraconazole (index inhibitor) compared to BV100 alone. No dose adjustment is anticipated

BV100 shows very good exposure in the ELF, with mean ratios calculated as CELF/Cplasma and AUCELF/AUCplasma of 51 and 36, respectively, underscoring the very good distribution of rifabutin into the lung

Source: Company information.

Note: 1. Rifampicin results in a 99% reduction; 2. As of September 30, 2024, including Phase 2 patients. q12h: twice daily dosing; AUC: Area Under the Curve; SAD: Single Ascending Dose; MAD: Multiple Ascending Dose; DDI: Drug-drug interaction; RI: Renally Impaired; HI: Hepatic Impaired; BAL: Bronchoalveolar lavage; Cmax: Peak drug concentration; CYP3A4: Cytochrome P450 3A4.

BV100 is considered safe and well tolerated, dosing q12h without any dose adjustments likely, 236² people dosed so far

PHASE 2 TRIAL IN VABP

Patients with Suspected or Confirmed Acinetobacter VABP

Source: Company information. Note: VABP: Ventilator Associated Bacterial Pneumonia; PK: Pharmacokinetics; q12h: Twice-daily dosing; Polymyxin B: Will be dosed according to international consensus guidelines; AE: Adverse Event; FPFV: First Patient First Visit; DSMB: Data and Safety Monitoring Board; LPLV: Last Patient Last Visit; 1. Treatment failure, VABP due to colistin-resistant Acinetobacter or patients with known intolerance to colistin.

The Phase 2 study was used to determine the safety and PK of BV100 to enable a final dose for the Phase 3 trial in order to de-risk the program

OVERVIEW OF ADVERSE EVENTS

Safety population¹

	Part A		Part B
	BV100 + Poly B (N=21)	BAT (N=10)	BV100 + BAT (N=8)
TEAE	19 (90.5%) 56	7 (70%) 22	8 (100%) 30
TEAE (Grade 3/4/5)2	13 (61.9%) 27	7 (70%) 11	7 (87.5%) 12
Serious TEAE	8 (38.1%) 11	6 (60%) 8	3 (37.5%) 4
Fatal TEAE	6 (28.6%) 6	6 (60%) 6	3 (37.5%) 3
SUSAR	0 (0%) 0	0 (0%) 0	0 (0%) 0
AESIs	0 (0%) 0	0 (0%) 0	0 (0%) 0
TEAE leading to BV100 discontinuation3	2 (9.5%) 2	NA	1 (12.5%) 1
Treatment-related TEAE (to BV100)	0 (0%) 0	NA	0 (0%) 0
Treatment-related TEAE (to Polymyxin B)	6 (29%) 6	NA	NA
Treatment-related SAE / deaths (to BV100)	0 (0%) 0	NA	0 (0%) 0
Treatment-related SAE / deaths (to Polymyxin B)	0 (0%) 0	NA	NA

¹Safety population includes patients randomized (part A) and assigned (part B) who received at least one dose of study treatment.

²grade 3 = severe AE, grade 4 = Life-threatening AE, grade 5 = AE result in death.

³Two patients in BV100 + Poly B arm experienced TEAE leading to BV100 discontinuation. The BV100 discontinuation was due to patient death rather than the TEAE itself, all BV100 doses were administered before death occurred.

TEAE = Treatment Emergent Adverse Event; SAE = Serious Adverse Event; AESI = Adverse Event of Special Interest; SUSAR = Suspected Unexpected Serious Adverse Reaction; BAT = Best Available Therapy; N = total number of subjects in the Safety Population. Results given as "n (%) E" where n=number of subjects with events, (%)=percentage, E=number of events.

BV100 is generally safe and well tolerated and safety profile is consistent with rifabutin

BV100 SHOWS CLEAR SURVIVAL BENEFIT

BV100 Part A versus BAT: Day 14 and Day 28 ACM in micro-ITT* (LPLV 27.09.2024)

* Positive, rapid diagnostic test showing the presence of A. baumannii

Source: Company information. Note: 1. The data is preliminary as the study is ongoing; Data as of August 8, 2024. 2. BAT failure; pan-drug resistant. ACM: All-cause Mortality; ITT: Intention to Treat; AB: Antibiotics; SOFA: Sequential Organ Failure Assessment; CPIS: Clinical Pulmonary Infection Score; PaO2: Partial pressure of oxygen; FiO2: Fraction of inspired oxygen; AEs: Adverse Events; SAEs: Serious Adverse Events; BAT: Best Available Therapy. ⁺Reference FDA briefing document 04.17.23

Phase 2 data suggest BV100 has a good survival benefit compared to best available therapy (BAT) in the mITT population. For comparison Xacduro showed a 12-13% benefit compared to colistin⁺

IMPROVED MICROBIOLOGICAL AND CLINICAL RESPONSE WITH BV100

BV100 Part A versus BAT: Carbapenem-resistant micro-ITT¹

¹Carbapenem-resistant Acinetobacter m-ITT population (Primary efficacy analysis population). ²Microbiological favorable response = eradication or presumed eradication; ³Clinical cure defined as at ToC (7 ± 2 days after End of Treatment). ⁴ Reference FDA briefing document 04.17.23.

BAT = Best Available Therapy ; ToC = Test of Cure ; ITT = Intend to Treat ; EOT= End of Treatment.

Phase 2 data suggest BV100 has a good microbiological response and clinical cure benefit compared to BAT. For comparison Xacduro showed a 21.6% and 26% benefit ⁴

PROPOSAL FOR A GLOBAL PHASE 3 TRIAL (CRAB: VABP, HABP, BSI)

Regulatory trial: A global Phase 3 Non-inferiority trial comparing BV100 versus Colistin

Clinical differentiating trial-> A global Phase 2b study comparing BV100 versus Best Available Therapy (BAT)

Endpoints

Primary endpoint

• 28-Day ACM

Safety endpoint

• Overview of AEs

Secondary Efficacy endpoints

• 14-day ACM
• Clinical cure rate
• Ventilator free days
• Time in ICU
• Time in Hospital

Trial design is validated either by CHMP or through precedents

Note: VABP: Ventilator Associated Bacterial Pneumonia, HABP: Hospital Associated Bacterial Pneumonia, BSI: Blood Stream Infection; AE: Adverse Event, ACM: All Cause Mortality; ICU: Intensive Care Unit; CHMP: Committee for Medicinal Products for Human Use.

Global Phase 3 trial design generally agreed with the FDA and EMA

ANTIBIOTIC DE-RISKING OCCURS EARLIER THAN IN OTHER TAS

Experience in Antibiotic Development Shows Important De-Risking Events Precede Late-Stage Efficacy Studies

Source: 1. Wouters et.al., "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018", JAMA. 2020;323(9):844–853. doi:10.1001/jama.2020.1166. Note: 2. As of September 30, 2024; 3. Two of the studies are ongoing; TA: Therapeutic Area; PK: Pharmacokinetics; PD: Pharmacodynamics; API: Active Pharmaceutical Ingredient.

ESTIMATING THE MARKET FOR BV100

Source: Company. 1. See Appendix - Market Definitions for a list of countries within each market; 2. DRG/Clarivate 2021 and epidemiology publications, including high and low risk infections; 3. Management estimate. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis - The Lancet 2022; 399: 629–55 Modeled estimates based on 2019 actuals, by the "Antimicrobial Resistance Collaborators"; 4. Based on duration of standard treatment procedures and BioVersys clinical protocol; 5. Akceso (3rd party) pricing study and partnership discussions, under current reimbursement environment. Note: 6. Calculated as the product of confirmed CRAB incidence, estimated treatment duration and daily net treatment price per geography. Note: CRAB: carbapenem-resistant strains.

PEAK SALES GUIDANCE FOR BV100

Source: Company. 1. See "Appendix - Market Definitions" page for a list of countries within each market; 2. DRG/Clarivate 2021 and epidemiology publications, including high and low risk infections (2027 projected incidence); 3. 2027 estimates of CRAB incidence based on Management assumptions of CRAB as a percent of AB infections supported by the following publications: U.S (Spellberg, 2013) , EU17 (Ayobami , 2020), Japan (Ikeda ,2011) , China (DRG) and Emerging Markets (Kim, 2018). The remainder of diagnosed A. baumannii cases are assumed to be Empiric therapy; 4. Akceso (3rd party) pricing study and partnership discussions, under current reimbursement environment. 5 Peak penetrations per geography are Management assumptions. 6. Assumes peak sales reached 9-years after product launch in each geography. Note: CRAB: carbapenem-resistant strains of Acinetobacter baumannii.

APRIL 2025 BIOVERSYS - PROPRIETARY MATERIAL

BV100 – DIFFERENTIATED MEDICAL BENEFITS

7 Clinical Trials Completed / Ongoing: Dosed in 2361 People
Company	Product	Distributes Well into Lung	No Pre-existing Resistance	Mode of Action	Approved API with Good Safety	Synergy with SoC	Development Phase
	BV100			NEW	✓		Phase 3 ready
Generic	Polymyxin / Colistin (Standard of Care)			N/A	Renal Tox		MARKETED
	XACDURO (Sul-Dur)			OLD	✓		MARKETED
	RG6006	?	?	NEW		?	1
	MEM-ANT3310			OLD		?	1
Polymyxin Analogs
	MRX-8			OLD			1
	SPR 206			OLD			2 1
	QPX9003			OLD			1
	OMN-6	?		NEW		?	1b/2a

Source: Company estimate based on public materials as of September 2024; indicative only. Note: 1. As of September 30, 2024; 2. Phase 2-ready.

BV100 is well differentiated vs. its competitors in development BV100 is well differentiated vs. its competitors in development

Alpibectir:

Pulmonary and

meningeal Tuberculosis

BIOVERSYS TACKLING THE TOP PRIORITY SUPERBUGS

ALPIBECTIR – NEW MARKET OPPORTUNITIES

Emerging Markets Need New TB Treatments Urgently

Estimated TB incidence rates, 2022

Source: WHO Global TB Report 2023

"Alpibectir Major Markets" includes Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Japan, Netherlands, Norway, Portugal, South Korea, Spain, Sweden, Switzerland, UK, USA; China & Alpibectir Emerging Markets" includes China, Belarus, Brazil, Bulgaria, Estonia, Hungary, Kazakhstan, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Algeria, Angola, Argentina, Egypt, Georgia, Indonesia, Kyrgyzstan, Malaysia, Morocco, Philippines, South Africa, Thailand, Ukraine, Uzbekistan, Vietnam, Afghanistan, Armenia, Azerbaijan, Bangladesh, Benin, Bolivia, Burkina Faso, Burma, Cambodia, Cameroon, Colombia, Cote D'Ivoire, DR Congo, Ethiopia, Ghana, India, Kenya, Madagascar, Malawi, Moldova, Mozambique, Nepal, Nigeria, Pakistan, Soudan, Tajikistan, Tanzania, Uganda, Zimbabwe and Zambia.

ETO BIOACTIVATION VIA A NOVEL PATHWAY

Source: Company information. Note 1. Patent filed in 61 countries; Eto: Ethionamide; Pto: Prothionamide; InhA: A gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.

The study has completed recruitment, and the data is being analysed

PHASE 2A: HUMAN PROOF OF CONCEPT ACHIEVED

AlpE Outperforms Eto Alone and Shows Comparable Activity to INH Preliminary Results¹

• ➢ Efficacy in time-to-positivity (TTP) from start to end of treatment
• ➢ The higher the TPP, the bigger is the EBA
• ➢ EBA studies are not statistically powered but identify clear trends
• ➢ Full topline data
• ➢ AlpE was well tolerated in the study

Source: Company information.

Note: 1. Data extract from March 2024: Efficacy data from PartA was QCed, efficacy data from PartB is not QCed yet. EBA: early bactericidal activity; TTP: time to sputum culture positivity; Eto: Ethionamide; INH: isoniazid. AlpE: alpibectir/Eto; Qced: quality-controlled; TB: tuberculosis; CSF: cerebrospinal fluid.

Alpibectir (first in class) delivered proof of concept in human. The combination of AlpE has the potential to become the fastest bactericidal TB drug, overcoming resistance and with exposure in the CSF

Estimated Daily Net Treatment Price by Country⁵ ~\$130 – \$150 \$1 – \$30 Major Markets¹ China & Emerging Markets¹ Indication Overview Acinetobacter Baumannii hospital and blood stream infections Pulmonary TB – Isoniazid Mono-Resistant Tuberculosis (INH Mono-Resistance TB), Multi-Drug Resistant Tuberculosis (MTR-TB); TB-Meningitis (TBM) # of Tuberculosis Cases (2028 Projected Incidence)² >50k >10.4m Estimated Total Addressable Market Potential ~\$1.1bn⁶ (2028) Estimated Treatment Duration⁴ 180 Days INH Mono-Resistance TB + MDR-TB + TBM Incidence³ ~17 ~4% ~12% ~2% Pulmonary TB TBM ESTIMATING THE MARKET FOR ALPIBECTIR

Note: 1. See "Appendix - Market Definitions" page for a list of countries within each market; 2. Projected incidence derived from WHO databases and considers certain assumptions from Management; 3. Management assumptions for 2028 incidence of INH Mono-Resistance TB derived from the following epidemiology publications: U.S (Iqbal, 2012) , Other High Income (Van der Werf 2014) , China (Xiao-chun He in Medicine 2015) and Other Upper/Mid Income Countries (Wang 2014 in PLOSone) and Mid to Low Income Countries; (Jenkins 2011 in PLOSone, 2018). Management assumptions for 2028 incidence of MDR-TB derived from the following epidemiology publications: China (L Wang et al, 2014), All other markets: (WHO Global TB report 2022). Management assumptions for 2028 incidence of TB-Meningitis derived from the following epidemiology publications: U.S and Other High-Income Counties (Nguyen et al, 2014), All other markets (Vanino et al, Flores et al); 4. Official WHO suggestion for treatment regimes; 5. Management estimates based on current average per market treatment costs, given current reimbursement environment. 6. Calculated as the product of confirmed incidence, estimated treatment duration and daily net treatment price per geography.

PEAK SALES GUIDANCE FOR ALPIBECTIR

INH-Resistant | MDR | TBM

		Major Markets1	China & Emerging Markets1
Geography	United States	Other High Income Countries	China	Other Upper / Mid Income Countries1	1 Mid / Low Income Countries
Est. # of TB cases2	7k	43k	645k	239k	>9.5m
INH-Resistant Rate MDR Rate TBM Rate3	7.5% 4.5% 2.0%	7.5% 4.5% 2.0%	12.5% 6.0% 4.0%	12.5% 4.5% 4.0%	12.5% 4.5% 4.0%
Pricing Range4	✓ Benchmarked against bedaquillin	✓ Benchmarked against bedaquillin	✓ Benchmarked against bedaquillin	✓ Benchmarked against bedaquillin	✓ Subject to NGO guidelines
Peak Market Share: INH Resistant MDR TBM5	~50% ~60% ~60%	~50% ~60% ~60%	~35% ~44% ~44%	~35% ~33% ~33%	~35% ~15% ~15%
Peak Sales by Geography6	~\$15m	~\$75m	~\$110m	~\$30m	~\$170m
Total Peak Sales6			~\$400m		Expected 50% share of peak sales with

Peak market share potential CRAB High risk | Empiric | CRAB Low risk

Source: Company. Note: 1. See "Appendix - Market Definitions" page for a list of countries within each market; 2. Projected incidence derived from WHO databases and considers certain assumptions from Management; 3. Management assumptions for 2028 incidence of INH Mono-Resistance derived from the following epidemiology publications: U.S (Iqbal, 2012) , Other High Income (Van der Werf 2014 , China (Xiao-chun He in Medicine 2015) and Other Upper/Mid Income Countries (Wang 2014 in PLOSone) and Mid to Low Income Countries; (Jenkins 2011 in PLOSone, 2018); Management assumptions for 2028 incidence of MDR-TB derived from the following epidemiology publications: China (L Wang et al, 2014), All other markets: (WHO Global TB report 2022); Management assumptions for 2028 incidence of TB-Meningitis derived from the following epidemiology publications: U.S and Other High-Income Counties (Nguyen et al, 2014), All other markets (Vanino et al, Flores et al); 4. Management estimates based on current average per market treatment costs, given current reimbursement environment; 5. Peak penetrations per geography, for treatment of INH-Resistant, MDR , and TBM are Management assumptions; 6. Assumes peak sales reached 7-9 years after product launch in each geography.

TB PARTNERSHIP WITH GSK EXTENDED TO REACH PATIENTS IN NEED

Completed		In Progress	Next Steps
Phase 1	Phase 2a	Phase 2	Phase 3
• Phase 1 (Complete): Study to investigate the safety, tolerability, PK in healthy volunteers (NCT04654143)	Phase 2a, AlpE-TB (ongoing): Study to evaluate the EBA, safety and tolerability of Eto alone and in combination with Alpibectir administered orally to adults with newly diagnosed, rifampicin and isoniazid susceptible pulmonary TB (NCT05473195)	TBM	• TBM offers potential for a small Phase 3 study based
		Phase 2 TBM (in planning): Study to evaluate the PK, safety and preliminary efficacy of AlpE in TBM patients in the treatment of TBM	on unmet medical need and LPAD • Based on exposure and efficacy from Phase 2 studies, label should include TBM and
• Eto-PK (Complete): Study to investigate the PKs of Eto and the active metabolite Eto-SO in patients on TB treatment (NCT05258877)		Pulmonary TB	pulmonary TB Decision • AlpE offers unique Point positioning in regimens based on its fast bactericidal activity
		Phase 2 in PTB (in planning): Additional studies with AlpE in combination with other anti-TB drugs in patients with pulmonary TB	• TBM & MDR pathway eligible for a priority review voucher1 after Phase 3 with estimated

Source: Company information. Note: AlpE: alpibectir/Eto; EBA: early bactericidal activity; Eto: Ethionamide; Eto-SO: Ethionamide-sulfoxide; MDR: multi-drug resistant; TBM: TB Meningitis; PTB: Pulmonary TB; LPAD: Limited population antibacterial drug. 1. FDA award for tropical diseases/illnesses related to public health emergencies; 2. Management assumption based on median purchase price of 3rd party vouchers from 2009-2019.

value of ~\$100M²

Next generation candidates & discovery platform

DISCOVERY PLATFORMS AND OTHER PIPELINE ASSETS

BV200 Overview BV500 Overview

Phase	Preclinical
Indication	Atopic dermatitis (mild – moderate)
MoA	Topical treatment – inhibits AgrA (accessory gene regulator A) and toxins production in S.aureus, preventing skin damage and flares
Platform	TRIC
Data-to-date	Preclinical data – in vivo efficacy (mouse models)
Next Milestone	Topical formulation suitable for preclinical tox

Source: Nature, Biopharm; Deal. 2021. Note: NCE: New chemical entity; Adapted from Campbell et al. Cell. 2001 mar 21;104(6): 901-12.

Phase	Preclinical
Indication	Non-tuberculous Mycobacteria (NTM) infections
MoA	Oral treatment – Novel NTM focused ansamycin class NCEs
Platform	Ansamycin
Data-to-date	Preclinical data – in vitro efficacy
Next Milestone	Selection of optimized Lead

TRIC Platform Ansamycin Platform

AMR – upside potential

GOOD PROGRESS HAS BEEN MADE WITH A RANGE OF INCENTIVES PILOTED ACROSS MAJOR MARKETS

39 Source: AMR Solutions, Center for Global Development, Charles River Associates; Policy solutions to commercial challenges in the fight against Antimicrobial Resistance, Charles River Associates; CCA CAC Overcoming Resistance, Expert Panel on Antimicrobial Availability. Note: 1. 118th Congress 1st Session Senate of the United States, April 2023; 2. Range is defined by unmet medical need addressed.

BIOVERSYS OPPORTUNITY

Note: 1. Numbers based on management assumptions, see p. 41, 42, 53 and 54 of this deck; 2. FDA award for tropical diseases/illnesses related to public health emergencies; 3. Management assumption based on median purchase of third-party vouchers from 2009-2019; 4. Prosthetic Joint Infections (PJI) Osteomyelitis. NTM: Non-tuberculous mycobacteria; MSSA: Methicillin-Sensitive Staphylococcus aureus; MRSA: Methicillin-resistant Staphylococcus aureus.

Financials

PROFIT AND LOSS – DECEMBER 31, 2024

in CHF million (based on consolidated IFRS financial statements)

• Other operating income includes grant income as well as research tax credits and remained at the same level compared to prior year.
• Lower R&D expenses for the year 2024 mainly due to fewer studies being conducted in the year 2024, as most BV100 phase 1 studies have been completed.
• Higher G&A expenses due to higher expenses for share-based payments and consultancy services (mainly IPO related)
• Higher finance result for the year 2024 mainly due to the change in the fair value measurement of the warrants (CHF 0.6 million) and the net foreign exchange gains/losses (CHF 0.3 million), partially compensated by an increase of interest expenses due to the disbursement of the 2nd EIB loan tranche in July 2023 (CHF 0.3 million).

BALANCE SHEET - DECEMBER 31, 2024

in CHF million (based on consolidated IFRS financial statements)

• Current assets comprise of cash and cash equivalents of CHF 26.6 million, current financial assets of CHF 6.0 million as well as prepaid expenses and other receivables of CHF 1.8 million.
• Equity increased by CHF 2.1 million mainly due to the capital increase of the Series C extension (CHF 14.7 million), the Conversion of the GIBF Investment into shares of BioVersys AG in December 2024 (CHF 5.2 million) and the reduction by the total net loss for the period (CHF 18.7 million).
• Non-current liabilities decreased mainly due to the reclassification of the BKB loan to current liabilities (CHF 2.9 million), partially equalized by additional interest expenses accrued for the EIB loan (CHF 0.9 million).
• Higher current liabilities mainly due to the reclassification of the BKB loan (CHF 2.9 million), additional accruals for services in relation with the IPO (CHF 0.7 million) and the decrease of prepayments for the Series C extension (CHF 2.8 million) which were converted into equity in Q2 2024.

CASH FLOW – DECEMBER 31, 2024

in CHF million (based on consolidated IFRS financial statements)

• Cash and cash equivalents (CHF 26.6 million) plus current financial assets (CHF 6.0 million) resulted in a cash position of CHF 32.6 million as of the end of 2024.
• Cash flow from operating activities was mainly driven by progression of the clinical trials for our lead project BV100 and working capital adjustments.
• Cash outflow from investing activities is related to the increase of short-term deposits with original maturities over three months (classified as current financial assets) in the year 2024.
• Cash flow from financing activities includes mainly proceeds on issue of shares (Series C extension) of CHF 14.7 million, the GIBF investment of CHF 5.1 million (capital increase by non-controlling interests) and the transaction costs of CHF 0.4 million.

Closing observations

INVESTING IN BIOTECH

Managing risk – creating upside

Known API Clinical

• Well understood safety
• Clear Mode of Action
• Killing bacteria really fast
• Clear clinical endpoints that can be measured

• Excellent safety in trials, as expected
• High concentrations of drug in target organ (lung)
• Clear clinical benefit- reducing mortality
• Clinicians in trial "want" to use BV100

• Phase 3 path generally agreed with regulators and precedent exists
• Endpoints allow commercial differentiation for reimbursement
• "easy to use" in ICU setting, positive feedback from physicians
• Company fully financed to deliver clinical results on Phase 3

BV100: Addressing AMR indication with limited/no treatment options with a clear path to success

UPDATED WHO PRIORITY PATHOGEN LIST 2024

High	High-medium	Medium	Medium-low	LOW
MR S. aureus	FQR Shigella spp.	3GCR E. coli	CR K. pneumoniae	CR A. baumannii
Macro-R Group A Streptococci	FQR nontyphoidal Salmonella	3GCR K. pneumoniae	Carbapenem-R E. coli	RR-TB
Macro-R S. pneumoniae	Ampi-R H. influenzae	VR E. faecium	FQR Salmonella Typhi
	Pen-R Group B Streptococci	FQR N. gonorrhoede	CR P. aeruginosa
		3GCR Enterobacter spp.	CR Enterobacter spp.
		3GCR Citrobacter spp.	3GCR N. gonorrhoeae
		3GCR Proteus spp.
		3GCR Serratia spp.
		3GCR Morganella spp.

Source: WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance.

BioVersys pipeline addresses with two clinical assets the two most difficult to treat priority pathogens of the world

COMPELLING INVESTMENT OPPORTUNITY

Leading the Fight to Overcome Life-threatening Infectious Diseases

Note: 1. Based on management assumptions, see pp. 41, 42, 53 and 54 of this deck of this presentation.

Q&A

Website: www.bioversys.com

IR mail: IR@bioversys.com